^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FIGNL1 overexpression

    i
    Other names: FIGNL1, Fidgetin Like 1, Fidgetin-Like Protein 1, Fidgetin-Like 1
    Entrez ID:
    63979
    over1year
    Exploring the Effect of Fidgetin-Like 1 on Colorectal Cancer Through Tissue Chip and In Vitro Experiments. (PubMed, Balkan Med J)
    Subsequent experiments demonstrated that FIGNL1-mediated P38 phosphorylation was contingent upon SPIDR interaction. These results implied that FIGNL1 was a potential anticancer drug target, which also offered a novel strategy for future CRC treatment.
    Preclinical • Journal
    |
    FIGNL1 (Fidgetin Like 1)
    |
    FIGNL1 overexpression
    over3years
    FIGNL1 is a potential biomarker of cisplatin resistance in non-small cell lung cancer. (PubMed, Int J Biol Markers)
    FIGNL1 is associated with poor prognosis in NSCLC, and cisplatin resistance may be involved. These observations provide a clinical basis for exploring FIGNL1 as a potential biomarker for cisplatin resistance in NSCLC.
    Retrospective data • Journal
    |
    HRD (Homologous Recombination Deficiency) • CCDC6 (Coiled-Coil Domain Containing 6) • RAD51 (RAD51 Homolog A) • FIGNL1 (Fidgetin Like 1)
    |
    FIGNL1 overexpression
    |
    cisplatin